Compositions comprising an inhibitor of lysine specific demethylase-1
US-10047069-B2 · Aug 14, 2018 · US
Compositions comprising an inhibitor of lysine specific demethylase-1
US10316016B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10316016-B2 |
| Application number | US-201816032002-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 10, 2018 |
| Priority date | Nov 5, 2015 |
| Publication date | Jun 11, 2019 |
| Grant date | Jun 11, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a crystalline form of a pharmaceutically acceptable salt of 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile, wherein the crystalline form of 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile can exist in unsolvated as well as solvated forms. 2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable salt is 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile besylate. 3. The pharmaceutical composition of claim 1 , wherein the solvated form comprises water or ethanol. 4. The pharmaceutical composition of claim 1 comprising about 0.5 mg to about 200 mg of crystalline 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile besylate salt. 5. A pharmaceutical composition comprising a crystalline form of a pharmaceutically acceptable salt of 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile and a residual amount of an organic solvent. 6. The pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable salt is 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile besylate. 7. The pharmaceutical composition of claim 5 , wherein the organic solvent is a Class 3 solvent. 8. The pharmaceutical composition of claim 1 , wherein an appropriate daily dosage is from about 1 to about 30 mg/kg per body weight.
Assignees
Inventors
Classifications
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
as doubly bound oxygen atom or as unsubstituted hydroxy radical · CPC title
not condensed and containing further heterocyclic rings · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10316016B2 cover?
- Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inh…
- Who is the assignee on this patent?
- Celgene Quanticel Res Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).